1

Miami Cancer Institute to Showcase Neuro-Oncology Research in Presentations at 2022 SNO Annual Meeting

 

MIAMI & TAMPA, FL – November 14, 2022 – Miami Cancer Institute, part of Baptist Health South Florida, today announced its oral and poster presentations at this year’s annual meeting of the Society for Neuro-Oncology (SNO), November 17-20, at the Tampa Convention Center in Tampa, Florida. The presentation topics include novel treatment approaches for glioblastoma and the latest in radiosurgery for brain metastases, among many others.

“The SNO annual meeting is a prime opportunity to showcase our leading-edge research in the field of neuro-oncology, which is an area of particular focus for us,” said Manmeet Singh Ahluwalia, M.D., chief of medical oncology, chief scientific officer, and deputy director of Miami Cancer Institute, and Fernandez Family Foundation Endowed Chair in Cancer Research. “Our physician-investigators at the Miami Cancer Institute have been leading several high-profile and promising trials that offer alternative treatment options and hope to patients affected by neurological tumors.”

 

Miami Cancer Institute’s oral and poster presentations at SNO 2022 include:

Oral Presentations

Friday, November 18, 2022
Phase II trial of SurVaxM plus temozolomide for newly diagnosed glioblastoma
Presenter: Manmeet S. Ahluwalia, M.D., MBA
Time: 4:25 p.m. ET
Location: Ballroom B

Randomized Phase II Open-Label Study of Nivolumab plus standard-dose Bevacizumab Vs Nivolumab plus low-dose Bevacizumab in Recurrent Glioblastoma (rGBM): Final report
Presenter: Manmeet S. Ahluwalia, M.D., MBA
Time: 5:15 p.m. ET
Location: Ballroom B

Poster Presentations

Friday, November 18, 2022
Clinical outcomes comparing radiosurgery techniques for managing large brain metastases
Presenter: Tugce Kutuk, M.D.
Time: 7:30 – 9:30 p.m. ET
Location: West/Central Hall

FIGHT-209: a phase 2, open-label, multicenter study of pemigatinib in patients with previously treated glioblastoma or other primary central nervous system tumors with activating FGFR1-3 alterations
Presenter: Manmeet S. Ahluwalia, M.D., MBA
Time: 7:30 – 9:30 p.m. ET
Location: West/Central Hall

Goldilocks and the Three Doses of Radiosurgery for Small Brain Metastases
Presenter: Tugce Kutuk, M.D.
Time: 7:30 – 9:30 p.m. ET
Location: West/Central Hall

Phase I study of Ibrutinib with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma
Presenter: Manmeet S. Ahluwalia, M.D., MBA
Time: 7:30 – 9:30 p.m. ET
Location: West/Central Hall

Phase 1 trial of ruxolitinib, temozolomide, and radiation in high-grade gliomas
Presenter: Manmeet S. Ahluwalia, M.D., MBA
Time: 7:30 – 9:30 p.m. ET
Location: West/Central Hall

Pivotal study to evaluate safety and efficacy of Exablate model 4000 using microbubble resonators to temporarily mediate blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE)
Presenter: Manmeet S. Ahluwalia, M.D., MBA
Time: 7:30 – 9:30 p.m. ET
Location: West/Central Hall

Prospective randomized phase II placebo-controlled trial of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE)
Presenter: Manmeet S. Ahluwalia, M.D., MBA
Time: 7:30 – 9:30 p.m. ET
Location: West/Central Hall

Randomized pivotal study of blood-brain barrier (BBB) disruption using Exablate Model 4000 with standard of care (SOC) therapy in non-small cell lung cancer (NSCLC) brain metastases: LIMITLESS trial
Presenter: Manmeet S. Ahluwalia, M.D., MBA
Time: 7:30 – 9:30 p.m. ET
Location: West/Central Hall

For updates from the SNO Annual Meeting, look for #SNO2022 on social media and follow Miami Cancer Institute on Twitter at @MiamiCancerInst.

 

###

 

About Miami Cancer Institute

Miami Cancer Institute brings to South Florida access to personalized clinical treatments and comprehensive support services delivered with unparalleled compassion. No other cancer program in the region has the combination of cancer-fighting expertise and advanced technology—including the first proton therapy center in South Florida, Latin America and the Caribbean, and one of the only radiation oncology programs in the world with each of the newest radiation therapies in one place—to diagnose and deliver precise cancer treatments that achieve the best outcomes and improve the lives of cancer patients. The Institute offers an impressive roster of established community oncologists and renowned experts, clinical researchers and genomic scientists recruited from the nation’s top cancer centers. Selected as Florida’s only member of the Memorial Sloan Kettering Cancer (MSK) Alliance, Miami Cancer Institute is part of a meaningful clinical collaboration that affords patients in South Florida access to innovative treatments and ensures that the standards of care developed by their multidisciplinary disease management teams match those at MSK.